Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 23

Cosmos Health Inc

COSMNASDAQ
Trade with Public
Trade with Public
$0.2215
0.00894.19%
가까이에: Aug 21, 5:00 PM EST
$0.2201
-0.0014-0.63%
시간외: Aug 21, 7:50 PM EST
실적: Q2 2026 실적이 화 8월 18th에 시장 마감 후 발표되었습니다.
개요뉴스실적 전망재무심리지분 현황비교옵션주식 보고서

Cosmos Health Earnings & Forecasts

Cosmos Health (COSM) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

Cosmos Health Guidance

Cosmos Health (COSM)는 7월 7, 2026에 Q2 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $19.4M - $19.4M 범위로 예상했습니다.

이전 가이던스와 비교하여 Cosmos Health는 매출 전망치를 이전 범위인 하향 조정됨에서 $200.6M - $200.6M로 상향 조정했습니다.

Cosmos Health은 9과 9월 18, 2024 사이에 7월 7, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 4 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

MetricQ2 '26Q1 '26Q4 '25Q3 '25
Earnings Per Share (Non-GAAP)
Estimate$0.01$-0.01$-0.05—
Actual$-0.10$-0.06$-0.04$-0.02
Surprise-1100.0%-500.0%+20.0%—
Revenue
Estimate$19.4M$21.9M$19.6M—
Actual$19.0M$17.9M$19.7M$17.1M
Surprise-2.24%-18.1%+0.66%—
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
MetricQ3 '26EQ4 '26EQ2 '27E
Earnings Per Share (Non-GAAP)
Consensus$-0.05$-0.03$0.01
Revenue
Consensus$20.9M$23.0M—
More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Cosmos Health Q2 EPS $(0.10) Misses $0.01 Estimate, Sales $18.986M Miss $19.420M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk

PRO
Cosmos Health Reports Preliminary Q2 Revenue Of $19.4M, Up 31.5% YoY, H1 Revenue Of $37.3M, Up ~31% YoY

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46
Benzinga Newsdesk

PRO
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a
Benzinga Newsdesk

PRO
Cosmos Health Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $17.928M Miss $21.893M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the
Benzinga Newsdesk

PRO
Cosmos Health Projects Cur18 Supplement To Generate $2.5M+ Annual Revenue Within 18-Months

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in
Benzinga Newsdesk

PRO
Cosmos Health Q4 Adj. EPS $(0.04), Inline, Sales $19.703M Beat $18.821M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 91.11 percent increase over losses of $(0.45) per share from the same period last year. The
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved